Quo-Test A1c System
Assay, Glycosylated Hemoglobin. 510(k) K180509, from Ekf-Diagnostic GmbH (Barleben, DE). Product code LCP, class 2.
As of Nov 20, 2026, K180509 is an FDA 510(k) held by Ekf-Diagnostic GmbH, substantially equivalent on Feb 16, 2019 after 354 days, with no recalls tied to it in FDA's recall database.
- Review time: 354 days
- Recalls: 0
The Quo-Test A1c System is intended for the in vitro quantitative determination of glycated hemoglobin (%HbA1c) levels in venous whole blood samples (using K2EDTA and lithium heparin anticoagulants). Measurement of percent glycated hemoglobin (%HbA1c) is effective for monitoring long-term glycemic control in individuals previously diagnosed with diabetes mellitus.
- Alere Afinion HbA1c, Alere Afinion AS100 AnalyzerK151809 · Alere Technologies AS · Sep 25, 2015
- Q-Pad Test SystemK231465 · Qurasense · Dec 6, 2023
- Document
- 510(k) summary (PDF) ↗
- Type
- Dual Track
- Received
- Feb 27, 2018
- Review panel
- Hematology
- Regulation
- 21 CFR 864.7470
One page per 510(k), De Novo and original PMA. Recalls are those FDA's recall database ties to this number; recalls of related devices that cite another number are not shown. Refreshed weekly. Predicates are read by Arca from the text of FDA's 510(k) summary PDFs, most of them scans: a device number counts when the summary names it as a predicate or as the device it is substantially equivalent to. About 97% of those read were right on a sample we checked by hand; summaries from before 2000 often name predicates without a number, so older devices show fewer. Pivotal studies are read by a model from FDA's De Novo decision summaries and PMA SSEDs; a count or result is shown only when its numbers appear in FDA's text. openFDA device 510(k), PMA and recall files